STOCKS TELEGRAPH

Tag: CVAC STOCK PRICE

  • CureVac (CVAC) Stock Surges After Favorable Patent Ruling

    CureVac (CVAC) Stock Surges After Favorable Patent Ruling

    CureVac N.V. (NASDAQ: CVAC) experienced a significant stock surge following a favorable decision in a patent dispute. The most recent market check showed that CVAC shares had increased 11.79% to $3.13. The spike comes after the European Patent Office (EPO) declared that CureVac’s European patent EP 3 708 668 B1 was still valid, although with changes to make its protections more clear.

    Opposition Dismissed, Patent Maintained

    The decision follows a hearing in which BioNTech SE’s arguments were generally rejected by the EPO’s opposition division. In April 2023, BioNTech first challenged the patent’s validity; nevertheless, the EPO’s ruling upheld its standing in a modified version.

    As CureVac continues to handle ongoing intellectual property challenges in Germany, this result represents a significant triumph. The six patents at the heart of the dispute between CVAC and BioNTech include the one that was upheld.

    Upcoming Infringement Ruling in Germany

    In light of this decision, the Düsseldorf Regional Court will have to decide whether BioNTech has violated the updated patent. The date of the infringement hearing is July 1, 2025.

    A decision in CureVac’s favor would start the process of determining possible damages. The EPO’s affirmation supports CVAC’s position that the updated patent is still enforceable and has been violated.

    The Dedication of CureVac to mRNA Innovation

    CureVac sees this court ruling as an important step in getting credit for its work on mRNA vaccine technology. The company has been at the forefront of messenger ribonucleic acid (mRNA) research, producing significant innovations such split poly-A tail technology, which enhances protein synthesis and improves vaccination efficacy.

    CureVac’s patented technology works on the basis of using customized mRNA as a data carrier to tell the body to make its own proteins that can combat a variety of ailments. CVAC remains steadfast in its determination to receive fair compensation for its innovations as it advances mRNA-based therapy in the US and European markets.

  • CureVac (CVAC): Strategic Restructuring Initiative Sparks Stock Surge

    CureVac (CVAC): Strategic Restructuring Initiative Sparks Stock Surge

    Following the announcement of a major strategic initiative, CureVac N.V. (NASDAQ: CVAC) witnessed a bullish trend in its shares on the US stock charts. The CVAC stock partially rebounded from a regular-session loss exceeding 6% by rising 4.49% in after-hours trading to $3.26.

    Focus on High-Value mRNA Projects

    In order to focus its efforts on high-value mRNA initiatives, notably in cancer and other areas with large unmet medical needs, CureVac (CVAC) has announced a significant strategic restructuring. The goal of this restructure is to create a smaller, more flexible corporation focused on technology innovation, research, and development.

    The reorganization comes after GSK and CVAC reached a new license deal worth up to €1.45 billion including royalties. As per the terms of this agreement, GSK will assume responsibility for the creation, production, and worldwide marketing of COVID-19 and influenza initiatives, including their combinations. This transition enables CureVac to concentrate on its core competencies.

    Advancements and Future Prospects

    CureVac has made notable progress in advancing its mRNA platform, demonstrated by promising Phase 2 data for influenza and COVID-19 and the recent GSK licensing agreement. The new GSK deal not only provides significant financial backing but also allows CureVac to streamline operations and emphasize technological innovation, research, and development. This change allows CVAC to better utilize mRNA technology in other areas for innovative therapeutic methods and to prioritize its cancer projects.

    CureVac anticipates reporting data from the Phase 1 study of its cancer vaccine candidate, CVGBM, in glioblastoma in the latter half of 2024. CureVac anticipates having two clinical candidates for shared-antigen cancer vaccines in solid tumors and hematological malignancies by the end of 2025, one of which will be developed in conjunction with M.D. Anderson researchers. The plan includes initiating two additional Phase 1 studies by the end of 2026.

    Financial Implications of Restructuring

    As a result of the restructuring, CureVac projects operational expenses will decrease by over 30% from 2025 onward, with personnel costs reducing by approximately €25 million. The company estimates one-time restructuring charges of around €15 million, which include employee severance, benefits, and related costs, to be incurred in the fourth quarter of 2024.

  • Here is why CureVac N.V. (CVAC) stock plunged in the after-hours on Wednesday?

    Here is why CureVac N.V. (CVAC) stock plunged in the after-hours on Wednesday?

    CureVac N.V. (CVAC) shares dipped 8.82% in after-hours on Wednesday, June 30, 2021, and closed at $67.00 per share. Earlier in the morning session, CVAC’s stock gained 8.92% to close Wednesday’s normal trading session at $73.48. CVAC shares have moved up by 29.12% in the past week. Over the past three months, the stock has lost 19.66%, while over the past six months, it has shed 13.42%.

    Let’s see why CVAC stock faced negativity in the after-hours on Wednesday?

    Low efficacy recorded in the final trial of COVID-19 CVnCoV vaccine

    On June 30, 2021, CureVac N.V. announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

    CVnCoV demonstrated an overall vaccine efficacy of only 48%against COVID-19 disease of any severity, including single non-respiratory mild symptoms.

    The efficacy of 53% was achieved among participants in the age group of 18 to 60.

    In the same age group, CVnCoV provided 100% protection (vaccine 0 vs. 6 placebo) against hospitalization or death. The data confirm the favourable safety profile of CVnCoV in all age groups.

    New appointments

    On June 30, 2021, CureVac N.V. appointed Dr. Malte Greune as Chief Operating Officer (COO) effective July 1, 2021.

    Dr Florian von der Mülbe, co-founder and Chief Production Officer of the company will also now focus his extensive production expertise exclusively on the expansion and accelerated development of The RNA Printer(R).

    On June 2, 2021, CureVac N.V. appointed Klaus Edvardsen, MD, Ph.D., as Chief Development Officer. The appointment of Dr. Edvardsen will take effect on August 1, 2021.

    Supervisory Board Update

    On June 23, 2021, CureVac N.V. announced that Dr. Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination to the Supervisory Board.

    Recent financial results announcement

    On May 26, 2021, CureVac N.V released its financial results for the first quarter of 2021.

    Q1 2021 financial highlights

    • CureVac reported revenue of €10.0 million for the first three months of 2021 compared to revenue of €3.1 million for the same period in 2020.
    • The company suffered from an operating loss of €115.8 million for the first three months of 2021 compared to an operating loss of €23.2 million for the same period in 2020.
    • The cost of sales and other operating expenses were €26.3 million for Q1 2021 compared to €125.8 million in Q1 2020.
    • As of March 31, 2021, the company had cash and cash equivalents of€1,497 million compared to €1,323 million as of December 31, 2020. 

    Conclusion

    The CVAC stock plummeted after the company announced that its Covid-19 vaccine shows 48% efficacy in the final analysis. The CVAC stock can further go down on Thursday as well because it’s a major setback for the company. 

  • Why CureVac BV (CVAC) stock plummeted on Wednesday after an important announcement?

    Why CureVac BV (CVAC) stock plummeted on Wednesday after an important announcement?

    CureVac N.V. (CVAC) shares plunged 45.67% in the after-hours on Wednesday, June 16, 2021, and close the session at $51.50 per share. Earlier, in the morning session, CVAC’s stock lost 3.47% to close Wednesday’s session at $94.79 per share. CVAC shares have moved down by 10.34% in the past week. Over the past three months, the stock has gained 0.53%, while over the past six months, it has shed 21.70%.

    Let’s try to find out why CVAC stock lost significantly on Wednesday?

    Update on Phase 2b/3 Trial ofCOVID-19 VaccineCVnCoV

    On June 16, 2021, CureVac N.V. announced the results of the second interim analysis of its international pivotal Phase 2b/3 study in approximately 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV.

    CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. The study is continuing to the final analysis and the totality of the data will be assessed for the most appropriate regulatory pathway.

    Earlier, on June 1, 2021, the company reported that the independent Data Safety Monitoring Board (DSMB) confirmed that the phase IIb/III study (HERALD) for CVnCoV has passed the first interim analysis in 59 adjudicated COVID-19 cases with no safety concerns.

    New appointment

    On June 2, 2021, CureVac N.V. appointed Klaus Edvardsen, MD, Ph.D., as Chief Development Officer. The appointment of Dr Edvardsen will take effect on August 1, 2021.

    Recent financial results announcement

    On May 26, 2021, CureVac N.V released its financial results for the first quarter of 2021.

    Q1 2021 financial highlights

    • CureVac reported revenue of €10.0 million for the first three months of 2021compared to revenue of €3.1 million for the same period in 2020.
    • The company suffered from an operating loss of €115.8 million for the first three months of 2021 compared to an operating loss of €23.2 million for the same period in 2020.
    • The cost of sales and other operating expenses were €26.3 million for Q1 2021 compared to €125.8 million in Q1 2020.
    • As of March 31, 2021, the company had cash and cash equivalents of€1,497 million compared to €1,323 millionas of December 31, 2020. 

    Conclusion

    The CVAC stock plummeted after the company announced that its Covid-19 vaccine shows 47% efficacy against Coronavirus variants. The CVAC stock can further go down on Thursday as well.